According to the Zhītōng Cáijīng APP, the biomedical stocks rebounded collectively. As of the submission, Remegen (09995) rose 8.06% to HKD 14.74; Kāi Lún Bó Tài shēngwù-B (06990) rose 7.46% to HKD 142.6; Gēn sī ruì shēngwù kējì (01548) rose 5.08% to HKD 9.52; and Jūn shí shēngwù (01877) rose 4.17% to HKD 13.

On the news front, on July 5, the State Council executive meeting passed the "Implementation Plan to Support the Development of Innovative Drugs throughout the Chain." Previously, the National Medical Insurance Bureau released a draft for soliciting opinions on "Notice on Establishing a First Publication Price Formation Mechanism for New-listed Chemical Drugs to Encourage High-quality Innovation." Local documents supporting the high-quality development of innovative drugs have been issued successively in Beijing, Guangzhou, Jinan and other places, focusing on access and payment and supporting the listing, hospitalization, and sales of innovative drugs.

Soochow Securities stated that the specific provisions of the "Implementation Plan to Support the Development of Innovative Drugs throughout the Chain" are expected to be implemented soon, coupled with the innovative drug sector being at a relatively low historical bottom, there are multiple catalytic factors such as the ESMO conference, WCLC conference, medical insurance negotiations, and expectations for the development of innovative drugs overseas in the second half of the year, and the innovative drug sector is expected to strengthen. Southwest Securities pointed out that in 2024, more than 30 domestically produced innovative drugs are expected to be approved for listing, and many excellent clinical data will be disclosed, which is expected to empower the company's performance and become an important catalyst for the stock price.